

NEWS RELEASE

**Telo Genomics Appoints former Roche Executive Guido Baechler
Chairman of the Board of Directors**

Toronto, Ontario, May 06, 2020 – Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the appointment of Guido Baechler as chairman of the Company’s Board of Directors. Mr. Baechler first joined the TELO Board of Directors on February 28, 2019 as an independent director and assumed the role of lead director on December 5, 2019. He is an international life science executive with over 25 years of experience in the commercialization of medical diagnostics.

“I look forward to leading the development of Telo Genomics’ innovative tests from clinical research to commercial products. Leveraging more than 20 years of genomic instability research, TELO’s liquid biopsy platform is designed to provide clinically actionable information to improve prognostic and therapeutic management for cancer and cognitive diseases,” said Mr. Baechler, chairman of TELO. “We see a number of commercial opportunities for the Company based on the existing product pipeline. Our TeloView® platform is engineered to be easy for clinical laboratories to implement, and our Toronto-based testing facility is capable of providing impactful precision medicine data to pharma and biotech companies to enhance drug development.”

Mr. Baechler recently founded a diagnostic and pharma consulting business that designs and leads strategic mergers, acquisitions, financing and research & development for start-up companies. Mr. Baechler advanced his diagnostics career at Roche Molecular Diagnostics, where he served as Vice President of Global Program Management and a member of its executive team. He previously held various leadership positions at Roche within Research, Development, and Marketing in Switzerland and California during his almost twenty years with the company. More recently, Mr. Baechler held the position of Chief Executive Officer and Senior Vice President of Operations (COO) at Singulex. Mr. Baechler holds a Bachelor’s Degree in Electrical Engineering and completed a series of executive finance and management classes at the London School of Business and the Haskins Business School at the University of California, Berkeley.

The Company is also pleased to welcome John Meekison to the TELO Board of Directors. Mr. Meekison joined the Company’s board at its most recent annual general meeting, and he has since been appointed chair of the Audit Committee. Mr. Meekison is an experienced investment banker, public and private company CFO, and Chartered Professional Accountant (CPA).

Hugh Rogers has resigned as chairman and will remain a director of the Company.

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The

benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.

For further information, please contact:

Hugh Rogers

Director

416-673-8487

info@telodx.com

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7

www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView™ platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.